カテゴリ： LP Information, 世界, 医療/バイオ

サトラリズマブの世界市場2022-2028：溶液、注射

■ 英語タイトル：Global Satralizumab Market Growth 2022-2028
	■ 発行会社/調査会社：LP Information ■ 商品コード：LP22DC5052 ■ 発行日：2022年12月 ■ 調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ■ 産業分野：医薬品 ■ ページ数：74 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後2-3営業日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥556,320	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥834,480	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,112,640	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[サトラリズマブの世界市場2022-2028：溶液、注射]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

サトラリズマブのグローバル市場規模は、2021年のxxx百万ドルから2028年までにxxx百万ドルに増加すると推定されており、2022年～2028年の年平均成長率（CAGR）はxx%を示しています。COVID-19とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対するパンデミックの直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
サトラリズマブのアジア太平洋市場は、2022年にxxx百万ドルの市場規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。サトラリズマブの米国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。サトラリズマブのヨーロッパ市場は、2022年にxxx百万ドルの規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。サトラリズマブの中国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要なサトラリズマブ関連企業としては、Hoffmann La Roche、 Genentech Inc.、 CHUGAI PHARMACEUTICAL CO.,LTD.などをカバーしています。売上の面では世界最大の2社が2021年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながらサトラリズマブのグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリューチェーン分析などのミクロの詳細にまで及びます。当レポートは読者がパンデミックおよびロシア・ウクライナ戦争中に世界中でサトラリズマブ市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、サトラリズマブのグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2021年で、市場の予測は2022年～2028年までのものです。

*** 市場セグメンテーション ***

この調査ではサトラリズマブ市場を細分化し、種類別 (溶液、注射)、用途別 (視神経脊髄炎治療、視神経脊髄炎予防、その他)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：溶液、注射

・用途別区分：視神経脊髄炎治療、視神経脊髄炎予防、その他

・地域別区分
アメリカ州（アメリカ、カナダ、メキシコ、ブラジル）
APAC/アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

*** 各章の紹介 ***
第1章：サトラリズマブの範囲、調査方法など
第2章：エグゼクティブサマリー、世界のサトラリズマブ市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2017年～2022年までの推移データ、および2028年までの市場予測
第3章：企業別サトラリズマブの販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章：地域別および国別のサトラリズマブの販売量と売上（米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど）
第5/6/7/8章：アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章：市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章：製造コスト構造分析
第11章：販売チャンネル、販売業者および顧客
第12章：地域別、国別、種類別、用途別の世界のサトラリズマブ市場規模予測
第13章：主要企業の包括的な企業プロファイル
第14章：調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：サトラリズマブの年間販売量2017-2028、地域別現状・将来分析
・サトラリズマブの種類別セグメント：溶液、注射
・サトラリズマブの種類別販売量：2017-2022年の販売量、売上、市場シェア、販売価格
・サトラリズマブの用途別セグメント：視神経脊髄炎治療、視神経脊髄炎予防、その他
・サトラリズマブの用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界のサトラリズマブ市場
・企業別のグローバルサトラリズマブ市場データ：2020-2022年の年間販売量、市場シェア
・企業別のサトラリズマブの年間売上：2020-2022年の売上、市場シェア
・企業別のサトラリズマブ販売価格
・主要企業のサトラリズマブ生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

サトラリズマブの地域別レビュー
・地域別のサトラリズマブ市場規模2017-2022：年間販売量、売上
・主要国別のサトラリズマブ市場規模2017-2022：年間販売量、売上
・アメリカ州のサトラリズマブ販売の成長
・アジア太平洋のサトラリズマブ販売の成長
・ヨーロッパのサトラリズマブ販売の成長
・中東・アフリカのサトラリズマブ販売の成長

アメリカ州市場
・アメリカ州の国別のサトラリズマブ販売量、売上（2017-2022）
・アメリカ州のサトラリズマブの種類別販売量
・アメリカ州のサトラリズマブの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋（APAC）市場
・アジア太平洋の国別のサトラリズマブ販売量、売上（2017-2022）
・アジア太平洋のサトラリズマブの種類別販売量
・アジア太平洋のサトラリズマブの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別のサトラリズマブ販売量、売上（2017-2022）
・ヨーロッパのサトラリズマブの種類別販売量
・ヨーロッパのサトラリズマブの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別のサトラリズマブ販売量、売上（2017-2022）
・中東・アフリカのサトラリズマブの種類別販売量
・中東・アフリカのサトラリズマブの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・サトラリズマブの製造コスト構造分析
・サトラリズマブの製造プロセス分析
・サトラリズマブの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・サトラリズマブの主要なグローバル販売業者
・サトラリズマブの主要なグローバル顧客

地域別のサトラリズマブ市場予測レビュー
・地域別のサトラリズマブ市場規模予測（2023-2028）
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・サトラリズマブの種類別市場規模予測
・サトラリズマブの用途別市場規模予測

主要企業分析
Hoffmann La Roche、 Genentech Inc.、 CHUGAI PHARMACEUTICAL CO.,LTD.
・企業情報
・サトラリズマブ製品
・サトラリズマブ販売量、売上、価格、粗利益（2020-2022）
・主要ビジネス概要
・最新動向

調査の結果

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions in the optic nerve, spinal cord, brainstem, and cerebrum.
The global market for Satralizumab is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Satralizumab market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Satralizumab market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Satralizumab market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Satralizumab market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Satralizumab players cover Hoffmann La Roche, Genentech Inc. and CHUGAI PHARMACEUTICAL CO.,LTD.. etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

[Report Coverage]
This latest report provides a deep insight into the global Satralizumab market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Satralizumab market, with both quantitative and qualitative data, to help readers understand how the Satralizumab market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the Satralizumab market and forecasts the market size by Type (Solution and Injection,), by Application (Treating Neuromyelitis Optica, Prevention of Neuromyelitis Optica and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Solution
Injection
Segmentation by application
Treating Neuromyelitis Optica
Prevention of Neuromyelitis Optica
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Hoffmann La Roche
Genentech Inc.
CHUGAI PHARMACEUTICAL CO.,LTD.

[Chapter Introduction]
Chapter 1: Scope of Satralizumab, Research Methodology, etc.
Chapter 2: Executive Summary, global Satralizumab market size (sales and revenue) and CAGR, Satralizumab market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Satralizumab sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Satralizumab sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Satralizumab market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Hoffmann La Roche, Genentech Inc. and CHUGAI PHARMACEUTICAL CO.,LTD., etc.
Chapter 14: Research Findings and Conclusion

*** レポート目次（コンテンツ）***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Satralizumab Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Satralizumab by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Satralizumab by Country/Region, 2017, 2022 & 2028
2.2 Satralizumab Segment by Type
2.2.1 Solution
2.2.2 Injection
2.3 Satralizumab Sales by Type
2.3.1 Global Satralizumab Sales Market Share by Type (2017-2022)
2.3.2 Global Satralizumab Revenue and Market Share by Type (2017-2022)
2.3.3 Global Satralizumab Sale Price by Type (2017-2022)
2.4 Satralizumab Segment by Application
2.4.1 Treating Neuromyelitis Optica
2.4.2 Prevention of Neuromyelitis Optica
2.4.3 Others
2.5 Satralizumab Sales by Application
2.5.1 Global Satralizumab Sale Market Share by Application (2017-2022)
2.5.2 Global Satralizumab Revenue and Market Share by Application (2017-2022)
2.5.3 Global Satralizumab Sale Price by Application (2017-2022)
3 Global Satralizumab by Company
3.1 Global Satralizumab Breakdown Data by Company
3.1.1 Global Satralizumab Annual Sales by Company (2020-2022)
3.1.2 Global Satralizumab Sales Market Share by Company (2020-2022)
3.2 Global Satralizumab Annual Revenue by Company (2020-2022)
3.2.1 Global Satralizumab Revenue by Company (2020-2022)
3.2.2 Global Satralizumab Revenue Market Share by Company (2020-2022)
3.3 Global Satralizumab Sale Price by Company
3.4 Key Manufacturers Satralizumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Satralizumab Product Location Distribution
3.4.2 Players Satralizumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Satralizumab by Geographic Region
4.1 World Historic Satralizumab Market Size by Geographic Region (2017-2022)
4.1.1 Global Satralizumab Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Satralizumab Annual Revenue by Geographic Region
4.2 World Historic Satralizumab Market Size by Country/Region (2017-2022)
4.2.1 Global Satralizumab Annual Sales by Country/Region (2017-2022)
4.2.2 Global Satralizumab Annual Revenue by Country/Region
4.3 Americas Satralizumab Sales Growth
4.4 APAC Satralizumab Sales Growth
4.5 Europe Satralizumab Sales Growth
4.6 Middle East & Africa Satralizumab Sales Growth
5 Americas
5.1 Americas Satralizumab Sales by Country
5.1.1 Americas Satralizumab Sales by Country (2017-2022)
5.1.2 Americas Satralizumab Revenue by Country (2017-2022)
5.2 Americas Satralizumab Sales by Type
5.3 Americas Satralizumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Satralizumab Sales by Region
6.1.1 APAC Satralizumab Sales by Region (2017-2022)
6.1.2 APAC Satralizumab Revenue by Region (2017-2022)
6.2 APAC Satralizumab Sales by Type
6.3 APAC Satralizumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Satralizumab by Country
7.1.1 Europe Satralizumab Sales by Country (2017-2022)
7.1.2 Europe Satralizumab Revenue by Country (2017-2022)
7.2 Europe Satralizumab Sales by Type
7.3 Europe Satralizumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Satralizumab by Country
8.1.1 Middle East & Africa Satralizumab Sales by Country (2017-2022)
8.1.2 Middle East & Africa Satralizumab Revenue by Country (2017-2022)
8.2 Middle East & Africa Satralizumab Sales by Type
8.3 Middle East & Africa Satralizumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Satralizumab
10.3 Manufacturing Process Analysis of Satralizumab
10.4 Industry Chain Structure of Satralizumab
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Satralizumab Distributors
11.3 Satralizumab Customer
12 World Forecast Review for Satralizumab by Geographic Region
12.1 Global Satralizumab Market Size Forecast by Region
12.1.1 Global Satralizumab Forecast by Region (2023-2028)
12.1.2 Global Satralizumab Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Satralizumab Forecast by Type
12.7 Global Satralizumab Forecast by Application
13 Key Players Analysis
13.1 Hoffmann La Roche
13.1.1 Hoffmann La Roche Company Information
13.1.2 Hoffmann La Roche Satralizumab Product Offered
13.1.3 Hoffmann La Roche Satralizumab Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Hoffmann La Roche Main Business Overview
13.1.5 Hoffmann La Roche Latest Developments
13.2 Genentech Inc.
13.2.1 Genentech Inc. Company Information
13.2.2 Genentech Inc. Satralizumab Product Offered
13.2.3 Genentech Inc. Satralizumab Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Genentech Inc. Main Business Overview
13.2.5 Genentech Inc. Latest Developments
13.3 CHUGAI PHARMACEUTICAL CO.,LTD.
13.3.1 CHUGAI PHARMACEUTICAL CO.,LTD. Company Information
13.3.2 CHUGAI PHARMACEUTICAL CO.,LTD. Satralizumab Product Offered
13.3.3 CHUGAI PHARMACEUTICAL CO.,LTD. Satralizumab Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 CHUGAI PHARMACEUTICAL CO.,LTD. Main Business Overview
13.3.5 CHUGAI PHARMACEUTICAL CO.,LTD. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Satralizumab Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Satralizumab Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Solution
Table 4. Major Players of Injection
Table 5. Global Satralizumab Sales by Type (2017-2022) & (K Units)
Table 6. Global Satralizumab Sales Market Share by Type (2017-2022)
Table 7. Global Satralizumab Revenue by Type (2017-2022) & ($ million)
Table 8. Global Satralizumab Revenue Market Share by Type (2017-2022)
Table 9. Global Satralizumab Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Satralizumab Sales by Application (2017-2022) & (K Units)
Table 11. Global Satralizumab Sales Market Share by Application (2017-2022)
Table 12. Global Satralizumab Revenue by Application (2017-2022)
Table 13. Global Satralizumab Revenue Market Share by Application (2017-2022)
Table 14. Global Satralizumab Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Satralizumab Sales by Company (2020-2022) & (K Units)
Table 16. Global Satralizumab Sales Market Share by Company (2020-2022)
Table 17. Global Satralizumab Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Satralizumab Revenue Market Share by Company (2020-2022)
Table 19. Global Satralizumab Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Satralizumab Producing Area Distribution and Sales Area
Table 21. Players Satralizumab Products Offered
Table 22. Satralizumab Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Satralizumab Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Satralizumab Sales Market Share Geographic Region (2017-2022)
Table 27. Global Satralizumab Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Satralizumab Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Satralizumab Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Satralizumab Sales Market Share by Country/Region (2017-2022)
Table 31. Global Satralizumab Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Satralizumab Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Satralizumab Sales by Country (2017-2022) & (K Units)
Table 34. Americas Satralizumab Sales Market Share by Country (2017-2022)
Table 35. Americas Satralizumab Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Satralizumab Revenue Market Share by Country (2017-2022)
Table 37. Americas Satralizumab Sales by Type (2017-2022) & (K Units)
Table 38. Americas Satralizumab Sales Market Share by Type (2017-2022)
Table 39. Americas Satralizumab Sales by Application (2017-2022) & (K Units)
Table 40. Americas Satralizumab Sales Market Share by Application (2017-2022)
Table 41. APAC Satralizumab Sales by Region (2017-2022) & (K Units)
Table 42. APAC Satralizumab Sales Market Share by Region (2017-2022)
Table 43. APAC Satralizumab Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Satralizumab Revenue Market Share by Region (2017-2022)
Table 45. APAC Satralizumab Sales by Type (2017-2022) & (K Units)
Table 46. APAC Satralizumab Sales Market Share by Type (2017-2022)
Table 47. APAC Satralizumab Sales by Application (2017-2022) & (K Units)
Table 48. APAC Satralizumab Sales Market Share by Application (2017-2022)
Table 49. Europe Satralizumab Sales by Country (2017-2022) & (K Units)
Table 50. Europe Satralizumab Sales Market Share by Country (2017-2022)
Table 51. Europe Satralizumab Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Satralizumab Revenue Market Share by Country (2017-2022)
Table 53. Europe Satralizumab Sales by Type (2017-2022) & (K Units)
Table 54. Europe Satralizumab Sales Market Share by Type (2017-2022)
Table 55. Europe Satralizumab Sales by Application (2017-2022) & (K Units)
Table 56. Europe Satralizumab Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Satralizumab Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Satralizumab Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Satralizumab Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Satralizumab Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Satralizumab Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Satralizumab Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Satralizumab Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Satralizumab Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Satralizumab
Table 66. Key Market Challenges & Risks of Satralizumab
Table 67. Key Industry Trends of Satralizumab
Table 68. Satralizumab Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Satralizumab Distributors List
Table 71. Satralizumab Customer List
Table 72. Global Satralizumab Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Satralizumab Sales Market Forecast by Region
Table 74. Global Satralizumab Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Satralizumab Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Satralizumab Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Satralizumab Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Satralizumab Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Satralizumab Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Satralizumab Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Satralizumab Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Satralizumab Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Satralizumab Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Satralizumab Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Satralizumab Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Satralizumab Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Satralizumab Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Satralizumab Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Satralizumab Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Satralizumab Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Satralizumab Revenue Market Share Forecast by Application (2023-2028)
Table 92. Hoffmann La Roche Basic Information, Satralizumab Manufacturing Base, Sales Area and Its Competitors
Table 93. Hoffmann La Roche Satralizumab Product Offered
Table 94. Hoffmann La Roche Satralizumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Hoffmann La Roche Main Business
Table 96. Hoffmann La Roche Latest Developments
Table 97. Genentech Inc. Basic Information, Satralizumab Manufacturing Base, Sales Area and Its Competitors
Table 98. Genentech Inc. Satralizumab Product Offered
Table 99. Genentech Inc. Satralizumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Genentech Inc. Main Business
Table 101. Genentech Inc. Latest Developments
Table 102. CHUGAI PHARMACEUTICAL CO.,LTD. Basic Information, Satralizumab Manufacturing Base, Sales Area and Its Competitors
Table 103. CHUGAI PHARMACEUTICAL CO.,LTD. Satralizumab Product Offered
Table 104. CHUGAI PHARMACEUTICAL CO.,LTD. Satralizumab Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. CHUGAI PHARMACEUTICAL CO.,LTD. Main Business
Table 106. CHUGAI PHARMACEUTICAL CO.,LTD. Latest Developments
List of Figures
Figure 1. Picture of Satralizumab
Figure 2. Satralizumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Satralizumab Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Satralizumab Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Satralizumab Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Solution
Figure 10. Product Picture of Injection
Figure 11. Global Satralizumab Sales Market Share by Type in 2021
Figure 12. Global Satralizumab Revenue Market Share by Type (2017-2022)
Figure 13. Satralizumab Consumed in Treating Neuromyelitis Optica
Figure 14. Global Satralizumab Market: Treating Neuromyelitis Optica (2017-2022) & (K Units)
Figure 15. Satralizumab Consumed in Prevention of Neuromyelitis Optica
Figure 16. Global Satralizumab Market: Prevention of Neuromyelitis Optica (2017-2022) & (K Units)
Figure 17. Satralizumab Consumed in Others
Figure 18. Global Satralizumab Market: Others (2017-2022) & (K Units)
Figure 19. Global Satralizumab Sales Market Share by Application (2017-2022)
Figure 20. Global Satralizumab Revenue Market Share by Application in 2021
Figure 21. Satralizumab Revenue Market by Company in 2021 ($ Million)
Figure 22. Global Satralizumab Revenue Market Share by Company in 2021
Figure 23. Global Satralizumab Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global Satralizumab Revenue Market Share by Geographic Region in 2021
Figure 25. Global Satralizumab Sales Market Share by Region (2017-2022)
Figure 26. Global Satralizumab Revenue Market Share by Country/Region in 2021
Figure 27. Americas Satralizumab Sales 2017-2022 (K Units)
Figure 28. Americas Satralizumab Revenue 2017-2022 ($ Millions)
Figure 29. APAC Satralizumab Sales 2017-2022 (K Units)
Figure 30. APAC Satralizumab Revenue 2017-2022 ($ Millions)
Figure 31. Europe Satralizumab Sales 2017-2022 (K Units)
Figure 32. Europe Satralizumab Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa Satralizumab Sales 2017-2022 (K Units)
Figure 34. Middle East & Africa Satralizumab Revenue 2017-2022 ($ Millions)
Figure 35. Americas Satralizumab Sales Market Share by Country in 2021
Figure 36. Americas Satralizumab Revenue Market Share by Country in 2021
Figure 37. United States Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC Satralizumab Sales Market Share by Region in 2021
Figure 42. APAC Satralizumab Revenue Market Share by Regions in 2021
Figure 43. China Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 47. India Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe Satralizumab Sales Market Share by Country in 2021
Figure 50. Europe Satralizumab Revenue Market Share by Country in 2021
Figure 51. Germany Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 52. France Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa Satralizumab Sales Market Share by Country in 2021
Figure 57. Middle East & Africa Satralizumab Revenue Market Share by Country in 2021
Figure 58. Egypt Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country Satralizumab Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of Satralizumab in 2021
Figure 64. Manufacturing Process Analysis of Satralizumab
Figure 65. Industry Chain Structure of Satralizumab
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

サトラリズマブの世界市場2022-2028：溶液、注射

グローバル市場調査会社